Characteristics and Treatments of Patients Enrolled in the CHAMP‐HF Registry Compared With Patients Enrolled in the PARADIGM‐HF Trial

BACKGROUND: The US Food and Drug Administration approved sacubitril/valsartan for patients with chronic heart failure (HF) with reduced ejection fraction in 2015 on the basis of the results of the PARADIGM‐HF (Prospective Comparison of ARNI [Angiotensin Receptor Neprilysin Inhibitor] With ACEI [Angi...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Am Heart Assoc
Auteurs principaux: DeVore, Adam D., Mi, Xiaojuan, Thomas, Laine, Sharma, Puza P., Albert, Nancy M., Butler, Javed, Hernandez, Adrian F., Patterson, J. Herbert, Spertus, John A., Williams, Fredonia B., Duffy, Carol I., McCague, Kevin, Fonarow, Gregg C.
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2018
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6220559/
https://ncbi.nlm.nih.gov/pubmed/29895587
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.118.009237
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires